HALIFAX, NS, April 19, 2022 /PRNewswire/ - ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the research, development and commercialization of advanced imageable ...
The MarketWatch News Department was not involved in the creation of this content. Final Patient Treated in FDA IDE Study Evaluating Eye90 microspheres(R) for the Treatment of Unresectable ...
HALIFAX, NS, May 30, 2023 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical ...
ABK Biomedical, Inc. announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers. This study is being ...
HALIFAX, NS, Nov. 19, 2024 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic ...
HALIFAX, NS, Feb. 24, 2026 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results